Larixyl acetate
Based on 3 publication(s) in Google Scholar
Larixyl acetate is a potent and selective TRPC6 inhibitor with IC50 values of 0.58 μM and 6.83 μM against hTRPC6-YFP and hTRPC3-YFP, respectively. Larixyl acetate prevents HPV and is effective in protecting against traumatic brain injury-induced systemic endothelial dysfunction.
For research use only. We do not sell to patients.
- Purity: 99.44%
- CAS No.: 4608-49-5
- Formula: C22H36O3
- Molecular Weight:348.52
-
Storage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
Publications Citing Use of MedChemExpress (MCE) Larixyl acetate
More
Biological Activity
|
hTRPC6 0.58 μM (IC50) |
hTRPC3 6.83 μM (IC50) |
Larixyl acetate (1-10 μM, 3 minutes) exerts its anti-inflammatory activity by inhibiting the phosphorylation of ERK1/2, AKT, and Src, suppressing fMLP-induced neutrophil migration, and inhibiting the interaction between βγ subunits and Src or PLCβ[2]. Larixyl acetate (5 μM, 1 hour) effectively improves TBI-induced aortic endothelial dysfunction by inhibiting TRPC6 activity[3]. Larixyl acetate (5 μM, 72 hours) significantly reduces the expression of ER stress genes and improves cell function in a cardiac hypertrophy cell model (H9c2 rat cardiomyocytes induced by Ang II)[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Human neutrophils
-
Concentration:1, 2, 5, 10 μM
-
Incubation Time:3 min
-
Result:Significantly inhibited fMLP-induced phosphorylation of ERK1/2, AKT, and Src.
-
Cell Line:H9c2 rat cardiomyocytes (cardiac hypertrophy model induced by Ang II (HY-13948))
-
Concentration:5 μM
-
Incubation Time:72 hours
-
Result:Significantly reduced the mRNA expression of cardiac hypertrophy-related genes (e.g., ANP, BNP, Myh7). Significantly reduced the expression of ER stress-related genes GRP78, pPERK, ATF4, and CHOP.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Closed-head mild traumatic brain injury (mTBI) model, C57BL/6, 129S, 129S-C57BL/6-F2 mice, TRPC6 knockout mice[3]
-
Dosage:5 mg/kg
-
Administration:Intraperitoneal injection (i.p.), once daily for 7 days
-
Result:Significantly improved aortic endothelial function 7 days after TBI. Caused that acetylcholine (10 μM) induced dilation was significantly enhanced in Larixyl acetate-treated mice (In C57BL/6 mice, the Larixyl acetate group showed 96.9 %; in 129S-C57BL/6-F2 mice, the Larixyl acetate group showed 89.2 %).
-
Animal Model:Transverse aortic constriction (Tac) model for pressure overload-induced heart failure in mice[5]
-
Dosage:5 mg/kg
-
Administration:Intraperitoneal injection (i.p.), once daily for 4 weeks
-
Result:Significantly reduced cardiac hypertrophy, left ventricular pressure, and improved cardiac function (FS and EF increased). Improved TAC-induced cardiac fibrosis, cardiomyocyte apoptosis, and inhibited ER stress-related proteins (e.g., GRP78) expression.
Chemical Information
-
CAS No. 4608-49-5
-
Appearance Solid
-
Molecular Weight 348.52
-
Formula C22H36O3
-
Color White to off-white
-
SMILES
CC(CCC1)(C)[C@]([C@@]1(C)[C@H]2CC[C@](C)(O)C=C)([H])[C@@H](OC(C)=O)CC2=C
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Publications (3)
-
Journal Impact Factor
-
Most Recent
-
Int J Mol Sci
2023 Nov 25;24(23):16756. PMID: 38069081 -
J Xenobiot
Phenotypic Subacute Toxicity Assessment of Intranasally Administered Larixyl Acetate: Implications for Potential Airway Applications. [Abstract]2026 Jun 1;16(3):100. PMID: 42346422 -
Mol Med Rep
Larixyl acetate, a TRPC6 inhibitor, attenuates pressure overload‑induced heart failure in mice. [Abstract]2024 Mar;29(3):49. PMID: 38275127
Solvent & Solubility
DMSO : 100 mg/mL (286.93 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (7.17 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (7.17 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (281 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Urban N, et al. Identification and Validation of Larixyl Acetate as a Potent TRPC6 Inhibitor. Mol Pharmacol. 2016 Jan;89(1):197-213. [Content Brief]
[2]. Liao HR, et al. Larixol inhibits fMLP-induced superoxide anion production and chemotaxis by targeting the βγ subunit of Gi-protein of fMLP receptor in human neutrophils. Biochem Pharmacol. 2022 Jul;201:115091. [Content Brief]
[3]. Chen X, et al. The TRPC6 inhibitor, larixyl acetate, is effective in protecting against traumatic brain injury-induced systemic endothelial dysfunction. J Neuroinflammation. 2019 Jan 31;16(1):21. [Content Brief]
[4]. Wang J, et al. The analgesic action of larixyl acetate, a potent TRPC6 inhibitor, in rat neuropathic pain model induced by spared nerve injury. J Neuroinflammation. 2020 Apr 16;17(1):118. [Content Brief]
[5]. Jia M, et al. Larixyl acetate, a TRPC6 inhibitor, attenuates pressure overload‑induced heart failure in mice. Mol Med Rep. 2024 Mar;29(3):49. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.8693 mL | 14.3464 mL | 28.6928 mL | 71.7319 mL |
| 5 mM | 0.5739 mL | 2.8693 mL | 5.7386 mL | 14.3464 mL | |
| 10 mM | 0.2869 mL | 1.4346 mL | 2.8693 mL | 7.1732 mL | |
| 15 mM | 0.1913 mL | 0.9564 mL | 1.9129 mL | 4.7821 mL | |
| 20 mM | 0.1435 mL | 0.7173 mL | 1.4346 mL | 3.5866 mL | |
| 25 mM | 0.1148 mL | 0.5739 mL | 1.1477 mL | 2.8693 mL | |
| 30 mM | 0.0956 mL | 0.4782 mL | 0.9564 mL | 2.3911 mL | |
| 40 mM | 0.0717 mL | 0.3587 mL | 0.7173 mL | 1.7933 mL | |
| 50 mM | 0.0574 mL | 0.2869 mL | 0.5739 mL | 1.4346 mL | |
| 60 mM | 0.0478 mL | 0.2391 mL | 0.4782 mL | 1.1955 mL | |
| 80 mM | 0.0359 mL | 0.1793 mL | 0.3587 mL | 0.8966 mL | |
| 100 mM | 0.0287 mL | 0.1435 mL | 0.2869 mL | 0.7173 mL |